TABLE 5

Mutation profile for each biomarker according to sex

Lung cancer in never smokers (BioCAST)Lung cancer in ever smokers#
MenWomenp-valueAll
Total n3847789
EGFR
 Patients n340
 Wild type35 (61)158 (56)0.438193 (57)
 Mutation22 (39)125 (44)147 (43)5%
  Data missing167
  in exon 181/21 (5)2/119 (2)NC3/140 (2)
  in exon 1912/21 (57)73/119 (61)85/140 (61)
  in exon 2007/119 (6)7/140 (5)
  in exon 218/21 (38)37/119 (31)45/140 (32)
KRAS
 Patients n293
 Wild type50 (94)223 (93)1.0273 (93)
 Mutation3 (6)17 (7)20 (7)32%
  Data missing22
  Transition06/15 (40)0.5156/18 (33)
  Transversion3/3 (100)9/15 (60)12/18 (67)
ALK
 Patients n192
 Wild type29 (94)139 (86)0.379168 (88)
 Mutation2 (6)22 (14)24 (13)4%
BRAF
 Patients n222
 Wild type34 (94)178 (96)0.667212 (95)
 Mutation2 (6)8 (4)10 (5)2%
HER2
 Patients n201
 Wild type32 (94)161 (96)0.625193 (96)
 Mutation2 (6)6 (4)8 (4)<1%
PI3KCA
 Patients n187
 Wild type30 (97)153 (98)0.519183 (98)
 Mutation1 (3)3 (2)4 (2)2%
  • Data are presented as n (%) or n/N available (%), unless otherwise stated. EGFR: epidermal growth factor receptor; KRAS: Kirsten rat sarcoma viral oncogene homologue; ALK: anaplastic lymphoma kinase; BRAF: v-Raf murine sarcoma viral oncogene homologue B; HER2: human epidermal growth factor receptor 2; PIK3CA: phosphatidylinositol-3-kinase, catalytic subunit α. #: Data from Biomarker France [22]; : Fisher's exact test; all other are Chi-squared test.